|
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm
|
5R44CA123994-05
|
$1,000,000
|
$330,000
|
Lebowitz, Michael
|
20/20 GENESYSTEMS, INC.
|
|
Unraveling the roles of VHL and hypoxia-inducible factor in VHL phenotypes
|
2R15CA121992-02A1
|
$283,108
|
$283,108
|
SCHOENFELD, ALAN
|
ADELPHI UNIVERSITY
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-37
|
$99,689
|
$997
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Community Clinical Oncology Program
|
5U10CA037422-24
|
$4,282,002
|
$42,820
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-35S1
|
$2,923,989
|
$29,240
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-35
|
$10,630,221
|
$106,302
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
$8,123
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
$5,697
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-08
|
$2,185,000
|
$2,185,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-13
|
$95,412
|
$954
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
|
5K08CA138900-02
|
$169,560
|
$169,560
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-03
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Pathway Specific Imaging in VHL Deficient Renal Cancer
|
1R01CA152330-01A1
|
$374,110
|
$374,110
|
SETH, PANKAJ
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-10
|
$320,196
|
$320,196
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
2R01CA109860-07
|
$328,499
|
$328,499
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Cancer and Leukemia Group B
|
3U10CA031946-30S1
|
$3,449,605
|
$68,992
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-30
|
$10,820,362
|
$216,407
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-27
|
$2,389,751
|
$23,898
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Computerized Monitoring Tool for MR-Guided Cryoablation
|
5R01CA152282-02
|
$525,652
|
$525,652
|
Tuncali, Kemal
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
$7,532
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
1U24CA160034-01
|
$3,034,910
|
$758,728
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
SBIR TOPIC 255 PHASE II: DEVELOPMENT OF ANTICANCER AGENTS
|
N44CO110113-000
|
$1,496,764
|
$299,353
|
BURKHART, CATHERINE
|
BUFFALO BIOLABS, LLC
|
|
Development and Validation of a FISH-Based Renal Cancer Detection Assay
|
5R44CA134103-03
|
$369,973
|
$369,973
|
HOULDSWORTH, JANE
|
CANCER GENETICS, INC.
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-28
|
$794,063
|
$7,941
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-37
|
$386,252
|
$3,863
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-22
|
$240,835
|
$2,408
|
Wilbur, Deborah
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
Heat Shock Protein Vaccine Targeting Carbonic Anhydrase IX in Renal Cell Carcinom
|
5K23CA120075-06
|
$146,059
|
$146,059
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
|
5R01CA133072-05
|
$55,462
|
$55,462
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cadherin-regulated apoptosis and survival signaling in epithelial cells
|
1R01CA142647-01A1
|
$358,629
|
$358,629
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL BOSTON
|
|
Pathophysiology of Post-Transplantation Cancer
|
5R01CA131145-03
|
$374,745
|
$374,745
|
Pal, Soumitro
|
CHILDREN'S HOSPITAL BOSTON
|
|
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
|
1R21CA155556-01
|
$191,835
|
$191,835
|
PERLMAN, ELIZABETH
|
CHILDREN'S MEMORIAL HOSPITAL (CHICAGO)
|
|
Genetics of pediatric rhabdoid tumors
|
5R01CA046274-20
|
$258,854
|
$88,010
|
BIEGEL, JACLYN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-25
|
$1,147,220
|
$11,472
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-24
|
$349,765
|
$13,991
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Sunitinib Modulation of Cancer Immunotherapy
|
5R01CA150959-02
|
$548,705
|
$548,705
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
CCOP: Colorado Cancer Research Program
|
5U10CA067753-16
|
$1,008,553
|
$10,086
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
5U10CA035261-28
|
$805,100
|
$8,051
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S5
|
$11,164,583
|
$223,292
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S6
|
$75,000
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
5U10CA032291-30
|
$469,660
|
$9,393
|
Burstein, Harold
|
DANA-FARBER CANCER INSTITUTE
|
|
ECOG Statistical Office
|
5U10CA023318-35
|
$2,311,793
|
$23,118
|
GRAY, ROBERT
|
DANA-FARBER CANCER INSTITUTE
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
2R01CA068490-16
|
$292,284
|
$292,284
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INSTITUTE
|
|
Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy
|
1R03CA156048-01
|
$83,156
|
$41,578
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INSTITUTE
|
|
Dayton Clinical Oncology Program
|
5U10CA035090-29
|
$945,951
|
$9,460
|
Gross, Howard
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA045807-26
|
$1,251,900
|
$12,519
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Eastern Cooperative Group Chair's Office
|
3U10CA086802-13S1
|
$2,561,235
|
$25,612
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Eastern Cooperative Group Chair's Office
|
5U10CA086802-13
|
$629,400
|
$6,294
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Cancer and Leukemia Group B
|
5U10CA047577-24
|
$95,798
|
$1,916
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-37S1
|
$37,988
|
$380
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
5P30CA014236-37
|
$5,723,821
|
$57,238
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
Total relevant funding to Kidney Disease for this search: $47,183,962
|